Northwestern Mutual Wealth Management Co. lowered its holdings in Bausch Health Companies Inc. (NYSE:BHC – Get Rating) by 92.8% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 16,066 shares of the company’s stock after selling 207,918 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Bausch Health Companies were worth $134,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Blueshift Asset Management LLC bought a new stake in shares of Bausch Health Companies during the first quarter worth $464,000. Metis Global Partners LLC bought a new stake in shares of Bausch Health Companies during the first quarter worth $254,000. Assetmark Inc. raised its position in shares of Bausch Health Companies by 454.3% during the second quarter. Assetmark Inc. now owns 10,421 shares of the company’s stock worth $87,000 after acquiring an additional 8,541 shares during the last quarter. Woodline Partners LP raised its position in shares of Bausch Health Companies by 1.1% during the first quarter. Woodline Partners LP now owns 1,013,462 shares of the company’s stock worth $23,158,000 after acquiring an additional 10,944 shares during the last quarter. Finally, Guardian Capital Advisors LP raised its position in shares of Bausch Health Companies by 73.8% during the first quarter. Guardian Capital Advisors LP now owns 63,690 shares of the company’s stock worth $1,447,000 after acquiring an additional 27,040 shares during the last quarter. Institutional investors and hedge funds own 70.07% of the company’s stock.
Analyst Ratings Changes
A number of equities research analysts have recently weighed in on BHC shares. Truist Financial downgraded Bausch Health Companies from a “buy” rating to a “hold” rating in a research report on Thursday, July 28th. Piper Sandler dropped their price objective on Bausch Health Companies from $7.00 to $6.00 and set a “neutral” rating for the company in a report on Friday, September 9th. JPMorgan Chase & Co. downgraded Bausch Health Companies from an “overweight” rating to a “neutral” rating in a report on Thursday, July 28th. Royal Bank of Canada upped their price objective on Bausch Health Companies from $4.50 to $8.00 and gave the company a “sector perform” rating in a report on Thursday, September 1st. Finally, StockNews.com started coverage on Bausch Health Companies in a report on Wednesday, October 12th. They issued a “hold” rating for the company. Five analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $10.60.
Bausch Health Companies Stock Up 12.3 %
Bausch Health Companies (NYSE:BHC – Get Rating) last announced its quarterly earnings results on Tuesday, August 9th. The company reported $0.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.89 by ($0.34). Bausch Health Companies had a return on equity of 942.47% and a net margin of 3.13%. The business had revenue of $1.97 billion during the quarter, compared to the consensus estimate of $2.05 billion. As a group, equities analysts predict that Bausch Health Companies Inc. will post 2.87 EPS for the current year.
Bausch Health Companies Company Profile
Bausch Health Companies Inc, together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products.
- Get a free copy of the StockNews.com research report on Bausch Health Companies (BHC)
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don’t Want to Get Stuck On
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
- Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
- Coupang Stock And Why You Should Care
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.